Literature DB >> 2470400

Recombinant polypeptides from the human immunodeficiency virus reverse transcriptase define three epitopes recognized by antibodies in sera from patients with acquired immunodeficiency syndrome.

C Padberg1, S Nowlan, B Mermer.   

Abstract

Eight fragments derived from the HIV-1 pol gene were expressed as recombinant polypeptides in Escherichia coli. The fragments were from the portion of the pol gene that encodes the reverse transcriptase. The expressed peptides were analyzed immunologically with sera from HIV-1-infected individuals. Three distinct immunogenic epitopes were identified. These determinants are presumably located on the surface of the native reverse transcriptase. Each epitope was included in a fusion protein that was expressed at high levels in bacteria. These proteins may provide reagents of potential diagnostic value.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2470400     DOI: 10.1089/aid.1989.5.61

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  4 in total

1.  Characterization of HIV-1 reverse transcriptase with antibodies indicates conformational differences between the RNAse H domains of p 66 and p 15.

Authors:  A M Szilvay; S Nornes; A Kannapiran; B I Haukanes; C Endresen; D E Helland
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

2.  Antibodies to the RNase H domain of hepatitis B virus P protein are associated with ongoing viral replication.

Authors:  T Weimer; F Schödel; M C Jung; G R Pape; A Alberti; G Fattovich; H Beljaars; P M van Eerd; H Will
Journal:  J Virol       Date:  1990-11       Impact factor: 5.103

3.  Two highly antigenic sites in the human immunodeficiency virus type 1 reverse transcriptase.

Authors:  E Björling; C A Boucher; A Samuelsson; T F Wolfs; G Utter; E Norrby; F Chiodi
Journal:  J Clin Microbiol       Date:  1993-03       Impact factor: 5.948

Review 4.  Mapping of viral epitopes with prokaryotic expression products.

Authors:  J A Lenstra; J G Kusters; B A van der Zeijst
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.